Therefore, PARK4 might be a useful target to investigate the mechanism through which DA neurons regulate α‐synuclein aggregation before the clinical onset of PD and could lead to the development of new therapies for patients with sporadic or familial PD. The gene discussed is SNCA; the disease is Parkinson disease.